Cargando…

PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1

Most deaths from breast cancer result from tumour recurrence, which is typically an incurable disease. Down-regulation of the pro-apoptotic tumour suppressor protein prostate apoptosis response-4 (PAR-4) is required for breast cancer recurrence and resistance to chemotherapy. Recent advances in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Haihong, Treude, Fabian, Krämer, Oliver H., Lüscher, Bernhard, Hartkamp, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584570/
https://www.ncbi.nlm.nih.gov/pubmed/31217499
http://dx.doi.org/10.1038/s41598-019-45209-9
_version_ 1783428535869767680
author Guo, Haihong
Treude, Fabian
Krämer, Oliver H.
Lüscher, Bernhard
Hartkamp, Jörg
author_facet Guo, Haihong
Treude, Fabian
Krämer, Oliver H.
Lüscher, Bernhard
Hartkamp, Jörg
author_sort Guo, Haihong
collection PubMed
description Most deaths from breast cancer result from tumour recurrence, which is typically an incurable disease. Down-regulation of the pro-apoptotic tumour suppressor protein prostate apoptosis response-4 (PAR-4) is required for breast cancer recurrence and resistance to chemotherapy. Recent advances in the analysis of apoptotic signalling networks have uncovered an important role for activation of caspase-8 following DNA damage by genotoxic drugs. DNA damage induces depletion of IAP proteins and causes caspase-8 activation by promoting the formation of a cytosolic cell death complex. We demonstrate that loss of PAR-4 in triple negative breast cancer cell lines (TNBC) mediates resistance to DNA damage-induced apoptosis and prevents activation of caspase-8. Moreover, loss of PAR-4 prevents DNA damage-induced cIAP1 depletion. PAR-4 functions downstream of caspase-8 by cleavage-induced nuclear translocation of the C-terminal part and we demonstrate that nuclear translocation of the C-terminal PAR-4 fragment leads to depletion of cIAP1 and subsequent caspase-8 activation. Specifically targeting cIAP1 with RNAi or Smac mimetics (LCL161) overcomes chemo-resistance induced by loss of PAR-4 and restores caspase-8 activation. Our data identify cIAP1 as important downstream mediator of PAR-4 and we provide evidence that combining Smac mimetics and genotoxic drugs creates vulnerability for synthetic lethality in TNBC cells lacking PAR-4.
format Online
Article
Text
id pubmed-6584570
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-65845702019-06-26 PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1 Guo, Haihong Treude, Fabian Krämer, Oliver H. Lüscher, Bernhard Hartkamp, Jörg Sci Rep Article Most deaths from breast cancer result from tumour recurrence, which is typically an incurable disease. Down-regulation of the pro-apoptotic tumour suppressor protein prostate apoptosis response-4 (PAR-4) is required for breast cancer recurrence and resistance to chemotherapy. Recent advances in the analysis of apoptotic signalling networks have uncovered an important role for activation of caspase-8 following DNA damage by genotoxic drugs. DNA damage induces depletion of IAP proteins and causes caspase-8 activation by promoting the formation of a cytosolic cell death complex. We demonstrate that loss of PAR-4 in triple negative breast cancer cell lines (TNBC) mediates resistance to DNA damage-induced apoptosis and prevents activation of caspase-8. Moreover, loss of PAR-4 prevents DNA damage-induced cIAP1 depletion. PAR-4 functions downstream of caspase-8 by cleavage-induced nuclear translocation of the C-terminal part and we demonstrate that nuclear translocation of the C-terminal PAR-4 fragment leads to depletion of cIAP1 and subsequent caspase-8 activation. Specifically targeting cIAP1 with RNAi or Smac mimetics (LCL161) overcomes chemo-resistance induced by loss of PAR-4 and restores caspase-8 activation. Our data identify cIAP1 as important downstream mediator of PAR-4 and we provide evidence that combining Smac mimetics and genotoxic drugs creates vulnerability for synthetic lethality in TNBC cells lacking PAR-4. Nature Publishing Group UK 2019-06-19 /pmc/articles/PMC6584570/ /pubmed/31217499 http://dx.doi.org/10.1038/s41598-019-45209-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Guo, Haihong
Treude, Fabian
Krämer, Oliver H.
Lüscher, Bernhard
Hartkamp, Jörg
PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
title PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
title_full PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
title_fullStr PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
title_full_unstemmed PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
title_short PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
title_sort par-4 overcomes chemo-resistance in breast cancer cells by antagonizing ciap1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584570/
https://www.ncbi.nlm.nih.gov/pubmed/31217499
http://dx.doi.org/10.1038/s41598-019-45209-9
work_keys_str_mv AT guohaihong par4overcomeschemoresistanceinbreastcancercellsbyantagonizingciap1
AT treudefabian par4overcomeschemoresistanceinbreastcancercellsbyantagonizingciap1
AT krameroliverh par4overcomeschemoresistanceinbreastcancercellsbyantagonizingciap1
AT luscherbernhard par4overcomeschemoresistanceinbreastcancercellsbyantagonizingciap1
AT hartkampjorg par4overcomeschemoresistanceinbreastcancercellsbyantagonizingciap1